{"id":881411,"date":"2025-09-03T08:29:38","date_gmt":"2025-09-03T12:29:38","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/"},"modified":"2025-09-03T08:29:38","modified_gmt":"2025-09-03T12:29:38","slug":"bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/","title":{"rendered":"BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET"},"content":{"rendered":"
\n

PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH) and Principal Investigator and Steering Committee Co-Chair for CALIBRATE, the Company\u2019s Phase 3 clinical trial for autosomal dominant hypocalcemia type 1 (ADH1).<\/p>\n

Dr. Gafni will provide an overview of ADH1, specifically focusing on pathophysiology, the current unmet need, and the rationale for evaluating encaleret as a treatment for ADH1.<\/p>\n

In addition to Dr. Gafni, executive members of the ADH1 program team will review the ongoing encaleret clinical development program and discuss the ongoing Phase 3 CALIBRATE study, for which topline results are expected in fall 2025.<\/p>\n

To access the live webcast of BridgeBio\u2019s investor webinar, please visit the \u201cEvents & Presentations\u201d page within the Investors section of the BridgeBio website at\u00a0http:\/\/investor.bridgebio.com<\/strong><\/a>. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.<\/p>\n

\n About BridgeBio Pharma, Inc.<\/strong>
\n
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio\u2019s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com<\/strong><\/a> and follow us on LinkedIn<\/strong><\/a>, Twitter<\/strong><\/a>,<\/a>Facebook<\/strong><\/a>, Instagram<\/strong><\/a>, and YouTube<\/strong><\/a>.<\/p>\n

\n BridgeBio Media Contact:<\/strong>
\n
Bubba Murarka, Executive Vice President
contact@bridgebio.com<\/a>\u00a0\u00a0
(650)-789-8220<\/p>\n

\n BridgeBio Investor Contact:<\/strong>
\n
Chinmay Shukla, Senior Vice President, Strategic Finance
ir@bridgebio.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH) and Principal Investigator and Steering Committee Co-Chair for CALIBRATE, the Company\u2019s Phase 3 clinical trial for autosomal dominant hypocalcemia type 1 (ADH1). Dr. Gafni will provide an overview of ADH1, specifically focusing on pathophysiology, the current unmet need, and the rationale for evaluating encaleret as a treatment for ADH1. In … <\/p>\n

Continue reading “BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-881411","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH) and Principal Investigator and Steering Committee Co-Chair for CALIBRATE, the Company\u2019s Phase 3 clinical trial for autosomal dominant hypocalcemia type 1 (ADH1). Dr. Gafni will provide an overview of ADH1, specifically focusing on pathophysiology, the current unmet need, and the rationale for evaluating encaleret as a treatment for ADH1. In … Continue reading "BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-03T12:29:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMDY3OCM3MTIyNDIxIzIxNTY5MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET\",\"datePublished\":\"2025-09-03T12:29:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\\\/\"},\"wordCount\":330,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMDY3OCM3MTIyNDIxIzIxNTY5MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\\\/\",\"name\":\"BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMDY3OCM3MTIyNDIxIzIxNTY5MjY=\",\"datePublished\":\"2025-09-03T12:29:38+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMDY3OCM3MTIyNDIxIzIxNTY5MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUyMDY3OCM3MTIyNDIxIzIxNTY5MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET - Market Newsdesk","og_description":"PALO ALTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webinar on Wednesday, September 10, 2025 at 8:00 am ET with Rachel Gafni, M.D., Senior Research Physician at the National Institute of Dental and Craniofacial Research, part of the National Institutes of Health (NIH) and Principal Investigator and Steering Committee Co-Chair for CALIBRATE, the Company\u2019s Phase 3 clinical trial for autosomal dominant hypocalcemia type 1 (ADH1). Dr. Gafni will provide an overview of ADH1, specifically focusing on pathophysiology, the current unmet need, and the rationale for evaluating encaleret as a treatment for ADH1. In … Continue reading \"BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/","og_site_name":"Market Newsdesk","article_published_time":"2025-09-03T12:29:38+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMDY3OCM3MTIyNDIxIzIxNTY5MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET","datePublished":"2025-09-03T12:29:38+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/"},"wordCount":330,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMDY3OCM3MTIyNDIxIzIxNTY5MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/","name":"BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMDY3OCM3MTIyNDIxIzIxNTY5MjY=","datePublished":"2025-09-03T12:29:38+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMDY3OCM3MTIyNDIxIzIxNTY5MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUyMDY3OCM3MTIyNDIxIzIxNTY5MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-to-host-autosomal-dominant-hypocalcemia-type-1-adh1-investor-webinar-on-wednesday-september-10th-at-800-am-et\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881411","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=881411"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/881411\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=881411"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=881411"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=881411"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}